China Clears GSK’s Relenza For Clinical Trials By Chinese Firms
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has cleared for clinical testing GlaxoSmithKline's Relenza (zanamivir) antiviral for treating avian flu. The drug is being developed under a licensing agreement in China between Nanjing Simcere Dongyuan Pharmaceutical and Nanjing EffactPharm Drug Development along with the Shanghai Institute of Materia Medica. Simcere has marketing rights from GSK in China, Indonesia, Thailand, Vietnam and other developing countries. (Click here for more